Adam Bucki
About
Adam Bucki is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry.
According to data from OpenAlex, Adam Bucki has authored 65 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 20 papers in Pharmacology and 19 papers in Organic Chemistry. Recurrent topics in Adam Bucki's work include Receptor Mechanisms and Signaling (22 papers), Cholinesterase and Neurodegenerative Diseases (17 papers) and Phosphodiesterase function and regulation (14 papers). Adam Bucki is often cited by papers focused on Receptor Mechanisms and Signaling (22 papers), Cholinesterase and Neurodegenerative Diseases (17 papers) and Phosphodiesterase function and regulation (14 papers). Adam Bucki collaborates with scholars based in Poland, Slovenia and Spain. Adam Bucki's co-authors include Marcin Kołaczkowski, Maciej Pawłowski, Agata Siwek, Monika Marcinkowska, Anna Wesołowska, Anna Partyka, Grzegorz Kazek, Elżbieta Pękala, Monika Głuch‐Lutwin and Agnieszka Zagórska and has published in prestigious journals such as International Journal of Molecular Sciences, Journal of Medicinal Chemistry and Molecules.
In The Last Decade
Adam Bucki
61 papers receiving 1.1k citations
Peers
Adam Bucki
Monika Głuch‐Lutwin Poland
Anna M. Waszkielewicz Poland
A. E. Medvedev Russia
Sonja Hinz Germany
Maciej Pawłowski Poland
Grzegorz Kazek Poland
Katarzyna Kulig Poland
Anna Rapacz Poland
Grzegorz Satała Poland
Citations per year, relative to Adam Bucki Adam Bucki (= 1×)
peers
Monika Głuch‐Lutwin
Countries citing papers authored by Adam Bucki
Since
Specialization
Citations
This map shows the geographic impact of Adam Bucki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam Bucki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam Bucki more than expected).
Fields of papers citing papers by Adam Bucki
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Adam Bucki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam Bucki. The network helps show where Adam Bucki may publish in the future.
Co-authorship network of co-authors of Adam Bucki
This figure shows the co-authorship network connecting the top 25 collaborators of Adam Bucki. A scholar is included among the top collaborators of Adam Bucki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam Bucki. Adam Bucki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Śniecikowska, Joanna, Monika Głuch‐Lutwin, Adam Bucki, et al.. (2025). Discovery of NLX-266, an Orally Available and Metabolically Stable ERK1/2-Biased 5-HT1AR Agonist with Superior Antidepressant and Antiparkinsonian Activity. Journal of Medicinal Chemistry. 68(9). 9706–9722.
2.
Wichur, Tomasz, Monika Głuch‐Lutwin, Barbara Mordyl, et al.. (2024). Exploring Novel GSK-3β Inhibitors for Anti-Neuroinflammatory and Neuroprotective Effects: Synthesis, Crystallography, Computational Analysis, and Biological Evaluation. ACS Chemical Neuroscience. 15(17). 3181–3201.
3.
Piska, Kamil, Adam Bucki, Paulina Koczurkiewicz, et al.. (2023). In Silico and In Vitro Assessment of Carbonyl Reductase 1 Inhibition Using ASP9521—A Potent Aldo-Keto Reductase 1C3 Inhibitor with the Potential to Support Anticancer Therapy Using Anthracycline Antibiotics. Molecules. 28(9). 3767–3767.
4.
Pasieka, Anna, Dawid Panek, Paula Zaręba, et al.. (2023). Novel drug-like fluorenyl derivatives as selective butyrylcholinesterase and β-amyloid inhibitors for the treatment of Alzheimer’s disease. Bioorganic & Medicinal Chemistry. 88-89. 117333–117333.
5.
Kurnik‐Łucka, Magdalena, Gniewomir Latacz, Adam Bucki, et al.. (2023). Neuroprotective Activity of Enantiomers of Salsolinol and N-Methyl-(R)-salsolinol: In Vitro and In Silico Studies. ACS Omega. 8(41). 38566–38576.
6.
Piska, Kamil, et al.. (2023). Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance. Xenobiotica. 53(6-7). 507–514.
7.
Więckowski, Krzysztof, Tomasz Wichur, Joanna Śniecikowska, et al.. (2022). Serotonin 5-HT6 Receptor Ligands and Butyrylcholinesterase Inhibitors Displaying Antioxidant Activity—Design, Synthesis and Biological Evaluation of Multifunctional Agents against Alzheimer’s Disease. International Journal of Molecular Sciences. 23(16). 9443–9443.
8.
Marcinkowska, Monika, Barbara Mordyl, Agata Siwek, et al.. (2022). Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression. European Journal of Medicinal Chemistry. 247. 115071–115071.
9.
Zagórska, Agnieszka, Adam Bucki, Anna Partyka, et al.. (2022). Design, synthesis, and behavioral evaluation of dual-acting compounds as phosphodiesterase type 10A (PDE10A) inhibitors and serotonin ligands targeting neuropsychiatric symptoms in dementia. European Journal of Medicinal Chemistry. 233. 114218–114218.
10.
Wichur, Tomasz, Anna Pasieka, Justyna Godyń, et al.. (2021). Discovery of 1-(phenylsulfonyl)-1H-indole-based multifunctional ligands targeting cholinesterases and 5-HT6 receptor with anti-aggregation properties against amyloid-beta and tau. European Journal of Medicinal Chemistry. 225. 113783–113783.
11.
Wichur, Tomasz, Justyna Godyń, Gniewomir Latacz, et al.. (2021). Development and crystallography-aided SAR studies of multifunctional BuChE inhibitors and 5-HT6R antagonists with β-amyloid anti-aggregation properties. European Journal of Medicinal Chemistry. 225. 113792–113792.
12.
Koczurkiewicz, Paulina, Kamil Piska, Agnieszka Gunia‐Krzyżak, et al.. (2020). Cinnamic acid derivatives as chemosensitising agents against DOX-treated lung cancer cells – Involvement of carbonyl reductase 1. European Journal of Pharmaceutical Sciences. 154. 105511–105511.
13.
Więckowska, Anna, Adam Bucki, Gniewomir Latacz, et al.. (2020). In Vitro and In Silico ADME-Tox Profiling and Safety Significance of Multifunctional Monoamine Oxidase Inhibitors Targeting Neurodegenerative Diseases. ACS Chemical Neuroscience. 11(22). 3793–3801.
14.
Śniecikowska, Joanna, Monika Głuch‐Lutwin, Adam Bucki, et al.. (2020). Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT 1A Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. Journal of Medicinal Chemistry. 63(19). 10946–10971.
15.
Bucki, Adam, Monika Marcinkowska, Joanna Śniecikowska, et al.. (2020). Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). European Journal of Medicinal Chemistry. 191. 112149–112149.
16.
Marcinkowska, Monika, Adam Bucki, Dawid Panek, et al.. (2019). Anti‐Alzheimer's multitarget‐directed ligands with serotonin 5‐HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activity. Archiv der Pharmazie. 352(7). e1900041–e1900041.
17.
Śniecikowska, Joanna, Monika Głuch‐Lutwin, Adam Bucki, et al.. (2019). Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT1A Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry. 62(5). 2750–2771.
18.
Więckowska, Anna, Tomasz Wichur, Justyna Godyń, et al.. (2018). Novel Multitarget-Directed Ligands Aiming at Symptoms and Causes of Alzheimer’s Disease. ACS Chemical Neuroscience. 9(5). 1195–1214.
19.
Śniecikowska, Joanna, Monika Głuch‐Lutwin, Adam Bucki, Paweł Mierzejewski, & Marcin Kołaczkowski. (2017). Functional selectivity – chance for better and safer drugs?. Postępy Psychiatrii i Neurologii. 26(3). 165–178.
20.
Więckowska, Anna, Marcin Kołaczkowski, Adam Bucki, et al.. (2016). Novel multi-target-directed ligands for Alzheimer's disease: Combining cholinesterase inhibitors and 5-HT 6 receptor antagonists. Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry. 124. 63–81.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Monika Głuch‐Lutwin Breakdown of academic impact, for papers by Anna M. Waszkielewicz Breakdown of academic impact, for papers by A. E. Medvedev Breakdown of academic impact, for papers by Sonja Hinz Breakdown of academic impact, for papers by Maciej Pawłowski Breakdown of academic impact, for papers by Grzegorz Kazek Breakdown of academic impact, for papers by Katarzyna Kulig Breakdown of academic impact, for papers by Anna Rapacz Breakdown of academic impact, for papers by Grzegorz Satała